Pregled bibliografske jedinice broj: 749661
Successful treatment in a patient with moderate- to-severe psoriasis with ustekinumab–case report
Successful treatment in a patient with moderate- to-severe psoriasis with ustekinumab–case report // Abstract book 2nd/19th Congress of Serbian Association of Dermatovenereologists
Beograd, Srbija, 2013. (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 749661 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Successful treatment in a patient with moderate- to-severe psoriasis with ustekinumab–case report
Autori
Bakija-Konsuo, Ana
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Abstract book 2nd/19th Congress of Serbian Association of Dermatovenereologists
/ - , 2013
Skup
2/19 Kongres udruženja dermatovenerologa Srbije
Mjesto i datum
Beograd, Srbija, 13.06.2013. - 14.06.2013
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
psoriasis; ustekinumab; side effects
Sažetak
We present a patient with long-standing, moderate-to-severe plaque psoriasis.He had a history of PV since the age of 38. His comorbidities included arterial hypertension and hyperlipidemia. The patient was anxious, the pruritus was extremely strong distracting him in everyday activities. His previous treatments included topical therapies (topical corticosteroids, vitamin D derivates), phototherapy and acitretin which were not effective or not tolerated. In June 2011 a treatment with ustekinumab was introduced at a dose of 90mg (107 kg) at week 0 and 4. After this injections of ustekinumab skin lesions were greatly improved. He continued treatment every 12 weeks. 18 monhts after the first injection there is only minimal disease activity, without any complication. The patient is extremely satisfied, he forgot his disease, he lost weight, and he successfully manages his everydays activities. In conclusion, this case report had demonstrated a high efficacy of the treatment with ustekinumab in our patient. The compliance is very good because of dosing every 12 weeks. The most improtant fact is the significant improvment of quality of life in our patient.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti